- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07631910
Application of Multimodal Intervention in the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery
Transcutaneous Electrical Acupoint Stimulation Versus Sham Stimulation Combined With Dexamethasone Versus Amisulpride for Preventing Postoperative Nausea and Vomiting After Laparoscopic Gynecological Surgery: A Randomized Controlled Factorial Trial
- Background Postoperative nausea and vomiting (PONV) is a common complication after general anesthesia, with an incidence as high as 80% in gynecological laparoscopic surgery. Transcutaneous electrical acupoint stimulation (TEAS) has shown potential as a non-invasive, side-effect-free intervention. Combining pharmacological agents (dexamethasone or amisulpride) with TEAS may provide a synergistic preventive effect, aligning with enhanced recovery after surgery (ERAS) principles.
Study Objectives To evaluate the preventive effect of TEAS on PONV in patients undergoing gynecological laparoscopic surgery, compared with sham stimulation.
To explore the synergistic effect of dexamethasone or amisulpride when combined with TEAS, and to optimize PONV prevention strategies.
To assess the impact of multimodal intervention on postoperative recovery quality, length of hospital stay, and patient satisfaction.
To evaluate the safety of the combined interventions and record any adverse events.
Study Design Design type: 2×2 factorial, randomized, double-blind (participants, outcome assessors, and data analysts blinded to group assignment).
Randomization: 1:1:1:1 allocation using an online randomization tool.
3.1 Study Groups Group Intervention A TEAS + Dexamethasone B TEAS + Amisulpride C Sham stimulation + Dexamethasone D Sham stimulation + Amisulpride 3.2 Participants Inclusion criteria: Age 18-65 years; ASA physical status I-II; scheduled for elective gynecological laparoscopic surgery (e.g., ovarian cystectomy, myomectomy) under general anesthesia; willing to provide informed consent.
Exclusion criteria: Severe cardiac, hepatic, renal, or pulmonary disease; allergy or skin disease at TEAS application site; Receipt of antiemetics within 24 h before surgery; Implanted cardiac pacemaker, cardioverter-;pregnancy or lactation; vulnerable populations (e.g., critically ill, psychiatric disorders, cognitive impairment, illiteracy); any condition deemed unsuitable by the investigator.
3.3 Interventions A wearable transcutaneous electrical acupoint stimulation (TEAS) wristband will be applied to the P6 (Neiguan) acupoint on the dominant upper extremity. The P6 acupoint is located approximately 3-5 cm proximal to the distal wrist crease, between the tendons of the flexor carpi radialis and palmaris longus. The device integrates the stimulating electrodes within the wristband and does not require external adhesive electrodes.
TEAS or sham stimulation will be administered at three time points: 30 minutes before surgery and 24 and 48 hours after surgery, with each session lasting 30 minutes.
Dexamethasone 5 mg (off-label for PONV; approved for inflammatory/allergic conditions).
Amisulpride 5 mg.
3.4 Outcome Measures
Primary outcomes (0-48 h postoperatively):
PONV incidence (proportion of patients with nausea, vomiting, or retching). PONV severity (0 = none, 1 = nausea only, 2 = vomiting/retching, 3 = refractory nausea/vomiting).
Secondary outcomes:
Recovery quality: time to first flatus, first ambulation, hospital stay, bowel function recovery.
Patient satisfaction: Visual Analogue Scale (VAS, 0-10) and QoR-15 score (0-150).
Rescue antiemetic use. Management needs for severe PONV. Postoperative pain (VAS at rest and on movement) and opioid consumption. Device-related adverse events (skin irritation, burning, allergy). Drug-related adverse events (e.g., hyperglycemia, hypotension, headache, dizziness, QT prolongation).
Intraoperative hemodynamics and postoperative complications (e.g., infection, shivering, urinary retention).
3.5 Follow-up Schedule Postoperative day 1 (24 h): PONV assessment, time to first flatus and ambulation.
Postoperative day 2 (48 h): PONV incidence/severity, rescue medication. At discharge: Satisfaction, hospital stay (via in-person or telephone follow-up).
Sample Size Calculation Assumptions: PONV incidence 50% in control groups, 30% in TEAS groups; two-sided α = 0.05; power = 80%.
Each main effect level requires ~93 patients. For a 2×2 factorial design with 1:1:1:1 allocation, this translates to 47 patients per group (total 188). Accounting for a 10% dropout rate, final sample size = 212 patients (53 per group).
Data Management and Confidentiality Electronic Data Capture (EDC) system with unique coding (no direct identifiers).
Access restricted to authorized research team members.
- Informed Consent Written informed consent will be obtained from each participant after full explanation of the study purpose, procedures, risks, and benefits. Participants are informed of their right to withdraw at any time.
- Adverse Event Management Dexamethasone-related AEs (transient hyperglycemia, blood pressure fluctuation, gastrointestinal discomfort, rare allergic reactions).
Amisulpride-related AEs (headache, dizziness, constipation/diarrhea, QT prolongation, allergic reactions).
TEA-related AEs (local skin discomfort, redness, itching, rare blisters or mild burns).
A tanulmány áttekintése
Állapot
Körülmények
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Zhengjie Chen, M.D.
- Telefonszám: 86 13634226323
- E-mail: chenzhengjie@zju.edu.cn
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Gang Chen, M.D.
- Telefonszám: 86 13757118681
- E-mail: chengang120@zju.edu.cn
Tanulmányi helyek
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kína, 310016
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
-
Kapcsolatba lépni:
- Youjia Yu, M.D.
- Telefonszám: 86 15995864437
- E-mail: yuyoujia0717@163.com
-
Kapcsolatba lépni:
- Xiujun Cai, M.D.
- Telefonszám: 0571-86090073
- E-mail: cxjzu@hotmail.com
-
Kutatásvezető:
- Zhengjie Chen, M.D.
-
Alkutató:
- Liangyu Zheng, M.D.
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- Age 18-65 years;
- ASA physical status I-II;
- Scheduled for elective gynecological laparoscopic surgery (e.g., ovarian cystectomy, myomectomy) under general anesthesia;
- Willing to provide informed consent.
Exclusion Criteria:
- Severe cardiac, hepatic, renal, or pulmonary disease;
- Allergy or skin disease at TEAS application site;
- Use of antiemetics within 24 hours before surgery; pregnancy or lactation;
- Vulnerable populations (e.g., critically ill, psychiatric disorders, cognitive impairment, illiteracy);
- Any condition deemed unsuitable by the investigator.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Megelőzés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Tényező hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: TEAS + Dexamethasone
Participants in this arm receive both transcutaneous electrical acupoint stimulation (TEAS) and dexamethasone. TEAS: Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator. Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation. The highest well-tolerated intensity will then be maintained for treatment. Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery. |
Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator.
Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively.
Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation.
The highest well-tolerated intensity will then be maintained for treatment.
|
|
Kísérleti: TEAS + Amisulpride
Participants in this arm receive both transcutaneous electrical acupoint stimulation (TEAS) and amisulpride. TEAS: Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator. Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation. The highest well-tolerated intensity will then be maintained for treatment. Amisulpride: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery. |
Applied at the P6 acupoint (located on the inner forearm, approximately 2 cun proximal to the wrist crease) using a transcutaneous electrical stimulator.
Stimulation is delivered for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively.
Stimulation intensity will be adjusted individually in a stepwise manner, starting from the lowest level and gradually increasing until the patient perceives a tolerable tingling or paresthesia sensation.
The highest well-tolerated intensity will then be maintained for treatment.
Amisulpride:Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
|
|
Kísérleti: Sham stimulation + Dexamethasone
Participants in this arm receive both sham transcutaneous electrical acupoint stimulation (TEAS) and dexamethasone. Sham stimulation: Electrodes are placed at the P6 acupoint (inner forearm, approximately 2 cun proximal to the wrist crease) for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. The device is attached but does not deliver any electrical output (no current). Participants are blinded to the stimulation status. Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery. |
Dexamethasone: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
|
|
Kísérleti: Sham stimulation + Amisulpride
Participants in this arm receive both sham transcutaneous electrical acupoint stimulation (TEAS) and amisulpride. Sham stimulation: Electrodes are placed at the P6 acupoint (inner forearm, approximately 2 cun proximal to the wrist crease) for 30 minutes at three time points: 30 minutes before surgery, 24 hours postoperatively, and 48 hours postoperatively. The device is attached but does not deliver any electrical output (no current). Participants are blinded to the stimulation status. Amisulpride: Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery. |
Amisulpride:Administered intravenously at a dose of 5 mg, 30 minutes before the end of surgery.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
PONV incidence within 48 hours postoperatively
Időkeret: within 48 hours
|
Proportion of patients experiencing nausea, vomiting, or retching.
|
within 48 hours
|
|
PONV severity
Időkeret: within 48 hours
|
Assessed using a 4-grade scale: Grade 0 = no nausea or vomiting Grade 1 = nausea only Grade 2 = vomiting or retching Grade 3 = refractory nausea and vomiting |
within 48 hours
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Nausea
Időkeret: 24 hours and 48 hours after surgery
|
The number of nausea episodes recorded after surgery
|
24 hours and 48 hours after surgery
|
|
Vomiting
Időkeret: 24 hours and 48 hours after surgery
|
The number of vomiting episodes recorded after surgery.
|
24 hours and 48 hours after surgery
|
|
Retching
Időkeret: 24 hours and 48 hours after surgery
|
The number of retching episodes recorded after surgery.
|
24 hours and 48 hours after surgery
|
|
Time to first flatus
Időkeret: Up to 48 hours after surgery
|
The time from the end of surgery to the first passage of flatus after transfer from the post-anesthesia care unit (PACU) to the ward.
|
Up to 48 hours after surgery
|
|
Time to first ambulation
Időkeret: Up to 48 hours after surgery
|
The time from the end of surgery to the patient's first out-of-bed activity.
|
Up to 48 hours after surgery
|
|
Length of hospital stay
Időkeret: Up to 7 days after surgery
|
Duration of postoperative hospitalization, measured in days.
|
Up to 7 days after surgery
|
|
Bowel function recovery
Időkeret: Up to 48 hours postoperatively
|
Assessed by the time of defecation.
|
Up to 48 hours postoperatively
|
|
Quality of recovery (QoR-15)
Időkeret: Up to 24 hours postoperatively
|
QoR-15 questionnaire score ranging from 0 to 150, covering 15 dimensions including physical comfort, emotional state, and psychological well-being.
|
Up to 24 hours postoperatively
|
|
Rescue antiemetic use
Időkeret: Up to 48 hours postoperatively
|
The type and number of rescue antiemetic medications required when a patient experiences PONV postoperatively.
|
Up to 48 hours postoperatively
|
|
Number of Participants Requiring Management for Severe PONV
Időkeret: Up to 48 hours postoperatively
|
Number of participants with severe postoperative nausea and vomiting, such as persistent vomiting or retching, requiring urgent additional amisulpride or other interventions.
|
Up to 48 hours postoperatively
|
|
Postoperative pain (VAS at rest)
Időkeret: Assessed at 24, 48, and 72 hours after surgery
|
Pain intensity measured at rest using a Visual Analogue Scale (0 = no pain, 10 = worst possible pain).
|
Assessed at 24, 48, and 72 hours after surgery
|
|
Postoperative pain (VAS on movement)
Időkeret: Assessed at 24, 48, and 72 hours after surgery
|
Pain intensity measured during movement (e.g., turning, coughing) using a Visual Analogue Scale (0 = no pain, 10 = worst possible pain).
|
Assessed at 24, 48, and 72 hours after surgery
|
|
Postoperative opioid consumption
Időkeret: Assessed at 48 hours after surgery.
|
Total amount of opioids consumed after surgery.
|
Assessed at 48 hours after surgery.
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Device-related adverse events
Időkeret: Assessed after TEAS treatment before surgery, 24 hours after surgery, and 48 hours after surgery.
|
Adverse events associated with TEAS or sham stimulation, including local skin irritation, burning sensation, redness, itching, blistering, or mild burns at the electrode site.
|
Assessed after TEAS treatment before surgery, 24 hours after surgery, and 48 hours after surgery.
|
|
Drug-related adverse events
Időkeret: Assessed at 24 and 48 hours after surgery.
|
Adverse events related to dexamethasone or amisulpride, including but not limited to headache, dizziness, constipation, diarrhea, facial flushing, QT prolongation, allergic reactions (rash, dyspnea, hypotension), transient hyperglycemia, and blood pressure fluctuations.
|
Assessed at 24 and 48 hours after surgery.
|
|
Proportion of Participants Receiving Intraoperative Vasoactive Drugs
Időkeret: Intraoperative period
|
Proportion of participants who received any vasoactive medication during surgery.
|
Intraoperative period
|
|
Postoperative complications
Időkeret: Up to 7 days after surgery
|
Occurrence of complications after surgery, including infection, shivering, and urinary retention.
|
Up to 7 days after surgery
|
|
Headache
Időkeret: 24 hours and 48 hours after surgery
|
Number of patients with postoperative headache
|
24 hours and 48 hours after surgery
|
|
Dizziness
Időkeret: 24 hours and 48 hours after surgery
|
Number of patients with postoperative dizziness
|
24 hours and 48 hours after surgery
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Tanulmányi szék: Youjia Yu, M.D., Sir Run Run Shaw Hospital
- Kutatásvezető: Gang Chen, M.D., Sir Run Run Shaw Hospital
- Tanulmányi igazgató: Zhengjie Chen, M.D., Sir Run Run Shaw Hospital
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Posztoperatív szövődmények
- Patológiás folyamatok
- Jelek és tünetek, emésztés
- Hányás
- Hányinger
- Kóros állapotok, jelek és tünetek
- Jelek és tünetek
- Posztoperatív hányinger és hányás
- Szerves vegyi anyagok
- Szénhidrogének
- Szénhidrogének, ciklikus
- Karbonsavak
- Szénhidrogének, aromás
- Policiklusos vegyületek
- Kialakulás
- Terhesség
- Terhesség
- Szteroidok
- Olvasztott gyűrűs vegyületek
- Szteroidok, fluortartalmú
- Benzolszármazékok
- Remoklóriumok
- Savak, karbociklusos
- Benzoátok
- Benzamidok
- Amiszulprid
- Dexametazon
Egyéb vizsgálati azonosító számok
- PONV
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
No participant consent for data sharing
Ethical approval does not permit it
Chinese regulations restrict sharing of sensitive health data
No data sharing agreement or infrastructure in place
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
az Egyesült Államokban gyártott és onnan exportált termék
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .